| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:129.)
© 2006 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, Oulu University Hospital, Finland (P.S, M.A., M.H.); the Department of Neurosurgery, Helsinki University Central Hospital, Finland (S.J.); the Department of Diagnostic Radiology, Oulu University Hospital, Finland (J.P.); the Department of Hematology (E.-R.S.), Oulu University Hospital, Finland.
Correspondence to Pertti Saloheimo, MD, Aurorankuja 4 E 20, 02940 Espoo, Finland. E-mail pertti.saloheimo{at}fimnet.fi
Background and Purpose Hematoma volume and impaired level of consciousness are the most potent predictors of outcome after spontaneous intracerebral hemorrhage (ICH). The effect of preceding aspirin-use on outcome after ICH is poorly investigated. We investigated short-term mortality and hematoma enlargement in subjects with ICH to find the predictors for these outcomes.
Methods This population-based study included all subjects with ICH during a period of 33 months in the population of Northern Ostrobothnia, Finland. The subjects were identified, and their clinical characteristics and outcomes were checked from hospital records or death records.
Results Three-month mortality of the 208 identified subjects with ICH was 33%. The independent risk factors for death were regular aspirin-use at the onset of ICH (relative risks [RR], 2.5; 95% CI, 1.3 to 4.6; P=0.004), warfarin-use at the onset of ICH (RR, 3.2; 95% CI, 1.6 to 6.1; P=0.001), and ICH score higher than 2 on admission (RR, 13.8; 95% CI, 6.0 to 31.4; P<0.001). Regular aspirin-use preceding the onset of ICH associated significantly with hematoma enlargement during the first week after ICH (P=0.006).
Conclusions We observed poor short-term outcomes and increased mortality, probably attributable to rapid enlargement of hematomas, in the subjects with ICH who had been taking regularly moderate doses of aspirin (median 250 mg) immediately before the onset of the stroke.
Key Words: aspirin cerebral hemorrhage mortality warfarin
Related Article:
Stroke 2006 37: 4-5.
This article has been cited by other articles:
![]() |
C. L. Roumie, E. F. Mitchel Jr, L. Kaltenbach, P. G. Arbogast, P. Gideon, and M. R. Griffin Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke Stroke, July 1, 2008; 39(7): 2037 - 2045. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Broderick, M. N. Diringer, M. D. Hill, N. C. Brun, S. A. Mayer, T. Steiner, B. E. Skolnick, S. M. Davis, and for the Recombinant Activated Factor VII Intracere Determinants of Intracerebral Hemorrhage Growth: An Exploratory Analysis Stroke, March 1, 2007; 38(3): 1072 - 1075. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Jauch, C. J. Lindsell, O. Adeoye, J. Khoury, W. Barsan, J. Broderick, A. Pancioli, and T. Brott Lack of Evidence for an Association Between Hemodynamic Variables and Hematoma Growth in Spontaneous Intracerebral Hemorrhage Stroke, August 1, 2006; 37(8): 2061 - 2065. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Foerch, M. Sitzer, H. Steinmetz, T. Neumann-Haefelin, and for the Arbeitsgruppe Schlaganfall Hessen Pretreatment With Antiplatelet Agents Is Not Independently Associated With Unfavorable Outcome in Intracerebral Hemorrhage Stroke, August 1, 2006; 37(8): 2165 - 2167. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Juvela and C. S. Kase Advances in Intracerebral Hemorrhage Management Stroke, February 1, 2006; 37(2): 301 - 304. [Full Text] [PDF] |
||||
![]() |
S. Tuhrim Aspirin-Use Before ICH: A Potentially Treatable Iatrogenic Coagulopathy? Stroke, January 1, 2006; 37(1): 4 - 5. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |